Robert S. Hogg CM is an HIV researcher focused on improving outcomes for people living with HIV/AIDS through the understanding of barriers to accessing HIV testing, treatment and care in Canada and globally.[1][2] He is a senior research scientist and the former Director of the HIV/AIDS Drug Treatment Program at the B.C. Centre for Excellence in HIV/AIDS.[3] He is a Simon Fraser University Distinguished Professor (the first to receive the title) and the Associate Dean of Research of the faculty of Health Sciences. He is a prolific and highly cited author with an H-index of 111 and over 1000 peer-reviewed papers.[4][5] He is both a Member of the Order of Canada and a Fellow of the Canadian Academy of Health Sciences.[1][6]
Robert S. Hogg | |
|---|---|
| Born | |
| Nationality | Canadian |
| Alma mater | Australian National University |
| Known for | Improving the Care of HIV Persons |
| Awards | Order of Canada, Royal Society of Canada |
| Scientific career | |
| Fields | HIV/AIDS |
| Institutions | British Columbia Centre for Excellence in HIV/AIDS |
His research includes, access to care including at risk-groups including those that use drugs or men that have sex with men, antiretroviral therapy, and aging with HIV.[7][8]
Access to Care
editDr. Hogg's research has extensively covered access and barriers to care such as his 1998 senior author paper looking at barriers to the use of free antiretroviral therapy in injection drug users.[9]
Antiretroviral Therapy
editHogg has published extensively on antiretroviral therapy from their inception to current times such as looking at antiretrovirals' effect on mortality.[10]
Drug resistance
editHogg's 2006 paper demonstrated that resistance to NNRTIs resulted in greater mortality than the development of resistance to protease inhibitors.[11]
Treatment as prevention strategy
editHogg, Julio Montaner and others are original authors of the Treatment as prevention strategy (TasP). The Treatment as Prevention strategy is based on the premise that administering highly active antiretroviral therapy to all medically eligible HIV-positive individuals will decrease transmission rates.[12][13]
External links
editReferences
edit- ^ a b General, Office of the Secretary to the Governor. "Dr. Robert Stephen Hogg". The Governor General of Canada.
- ^ "Celebrated BC-CfE researcher Dr. Robert Hogg named to Order of Canada". BC Centre for Excellence in HIV/AIDS. March 8, 2019.
- ^ "Dr. Robert Hogg | Clinical Care and Management (CCM)". CIHR Canadian HIV Trials Network.
- ^ "Robert Hogg". www.sfu.ca.
- ^ "Robert Hogg". scholar.google.com.
- ^ "Robert S Hogg – Health Research BC". www.msfhr.org.
- ^ "Robert Hogg". www.sfu.ca. Retrieved 2023-09-18.
- ^ "Hogg RS | BC Centre for Excellence in HIV/AIDS". www.bccfe.ca. Retrieved 2023-09-18.
- ^ Strathdee, SA; Palepu, A; Cornelisse, PG; Yip, B; O'Shaughnessy, MV; Montaner, JS; Schechter, MT; Hogg, RS (12 August 1998). "Barriers to use of free antiretroviral therapy in injection drug users". JAMA. 280 (6): 547–9. doi:10.1001/jama.280.6.547. PMID 9707146. S2CID 34963438.
- ^ Hogg, RS; O'Shaughnessy, MV; Gataric, N; Yip, B; Craib, K; Schechter, MT; Montaner, JS (3 May 1997). "Decline in deaths from AIDS due to new antiretrovirals". Lancet. 349 (9061): 1294. doi:10.1016/S0140-6736(05)62505-6. PMID 9142067. S2CID 26266152.
- ^ Hogg, Robert S.; Bangsberg, David R.; Lima, Viviane D.; Alexander, Chris; Bonner, Simon; Yip, Benita; Wood, Evan; Dong, Winnie W. Y.; Montaner, Julio S. G.; Harrigan, P. Richard (2006). "Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART". PLOS Medicine. 3 (9): e356. doi:10.1371/journal.pmed.0030356. PMC 1569883. PMID 16984218.
- ^ "CfE: Treatment as Prevention". 2012-01-25.
- ^ Montaner, JS; Hogg, R; Wood, E; Kerr, T; Tyndall, M; Levy, AR; Harrigan, PR (Aug 5, 2006). "The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic". Lancet. 368 (9534): 531–6. doi:10.1016/S0140-6736(06)69162-9. PMID 16890841. S2CID 11466139.